11 Advanced Solid Tumors Clinical Trials in Salt Lake City, UT (2026)

Q: How do I join a clinical trial in Salt Lake City?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you.

Recruiting Advanced Solid Tumors Studies in Salt Lake City

NCT05875168Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors....

Salt Lake City, UTPHASE1590 participantsDaiichi Sankyo

View Study Details

NCT06973564Recruiting

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of JAB-23E73 in adult participants with advanced solid tumors...

Salt Lake City, UTPHASE1294 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT06249048Recruiting

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Pati...

Salt Lake City, UTPHASE1108 participantsStrand Therapeutics Inc.

View Study Details

NCT05765851Recruiting

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors....

Salt Lake City, UTPHASE1108 participantsDaiichi Sankyo

View Study Details

NCT05490472Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....

Salt Lake City, UTPHASE1102 participantsJacobio Pharmaceuticals Co., Ltd.

View Study Details

NCT05135975Recruiting

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, a...

Salt Lake City, UTPHASE286 participantsNationwide Children's Hospital

View Study Details

NCT06352359Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose ...

Salt Lake City, UTPHASE172 participantsOncoC4, Inc.

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Salt Lake City, UTPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT06096974Recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or ...

Salt Lake City, UTPHASE160 participantsShanghai YingLi Pharmaceutical Co. Ltd.

View Study Details

NCT06721689Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). Th...

Salt Lake City, UTPHASE159 participantsTheodore Laetsch

View Study Details

NCT06358677Recruiting

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers wil...

Salt Lake City, UTPHASE225 participantsUniversity of Utah

View Study Details

About Advanced Solid Tumors Clinical Trials in Salt Lake City

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 11 advanced solid tumors clinical trials recruiting participants in Salt Lake City, UT. These studies are seeking a combined 1,569 participants. Research is being sponsored by Daiichi Sankyo, Jacobio Pharmaceuticals Co., Ltd., Strand Therapeutics Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Salt Lake City — FAQ

Are there advanced solid tumors clinical trials in Salt Lake City?

Yes, there are 11 advanced solid tumors clinical trials currently recruiting in Salt Lake City, UT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Salt Lake City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Salt Lake City research site will contact you about next steps.

Are clinical trials in Salt Lake City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Salt Lake City studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 11 active trials in Salt Lake City are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 18, 2026 from ClinicalTrials.gov